Pfizer for Oncology Professionals -- Clinical Library

SetPFPGroupVar.htm

SetPProProdListVar.htm

New User?

Returning User?

Benefits of registering

ppn-vr-sso-links.htm

E-mail

Search:

Below is a list of all Reprints. To narrow your search select a tumor type above

Showing 1 - 10 of 21 << Previous | 1 2 3 | Next >>

Title	Author	Publication Date	Source
1. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/ pharmacodynamic meta-analysis	Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ	December 2009	Cancer Chemother Pharmacol
2. Overall survival and updated results for sunitinib versus interferon alfa in first-line treatment of patients with metastatic renal cell carcinoma	Motzer RJ; Hutson TE; Tomczak P; et al	June 2009	J Clin Oncol
3. Metastatic breast cancer patients: addressing their unmet needs	MBC Advocacy Working Group	December 2008	Community Oncology
4. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial.	Cella D; Li JZ; Cappelleri JC; et al	August 2008	J Clin Oncol
5. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study	Marshall J; Mitchell E; Fuchs CS	October 2007	JCO
6. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007	Wood WC; Gelber RD; Goldhirsch A; et al	July 2007	Annals of Oncology
7. Survival and safety of exemestane versus tamoxifen after 2-3 years tamoxifen treatment (intergroup exemestane study): a randomised controlled trial	Snowdon CF; Coombes RC; Kilburn LS; et al	February 2007	Lancet
8. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study	Coleman R; Banks L; Girgis S; et al	January 2007	Lancet
9. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma	Motzer RJ; Hutson TE; Tomczak P;et al	January 2007	N Engl J Med
10. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial	Demetri GD; van Oosterom AT; Garrett CR; et al	October 2006	Lancet

Showing 1 - 10 of 21 << Previous | 1 2 3 | Next >>

In order to view these PDF documents, you must have Adobe^® Reader^® installed on your computer. If you do not have Adobe Reader, download it from the Adobe Web site.

Note that the Adobe Web site is neither owned nor controlled by Pfizer. Pfizer is not responsible for the content or services on that site.

Adobe, the Adobe logo, and Reader are registered trademarks of Adobe Systems Incorporated in the United States and/or other countries.

Important Safety Information for Aromasin

Important Safety Information for Camptosar

The information provided in this site is intended only for health care professionals in the United States.
The products discussed herein may have different product labeling in different countries.